Spruce Biosciences, Inc. Capital Expenditures
Spruce Biosciences, Inc. (SPRB) reported Capital Expenditures of $145.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-12
- Spruce Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $135.00K.
- Spruce Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $10.00K.
- Spruce Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-06-30 was $0.00.
- Spruce Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-03-31 was $0.00.
- Spruce Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Spruce Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $7.00K, a 12.50% decline from fiscal 2022.
- Spruce Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $8.00K, a 91.40% decline from fiscal 2021.
- Spruce Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2021 was $93.00K, a 25.68% increase from fiscal 2020.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $145.00K 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $10.00K 10-Q · filed 2026-05-13 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $0.00 10-K · filed 2025-04-15 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $7.00K derived: sum of 2 quarters · filed 2025-04-15 | $7.00K 10-K · filed 2025-04-15 | |
| 2023-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $7.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $2.00K derived: sum of 2 quarters · filed 2024-03-18 | $8.00K 10-K · filed 2024-03-18 | |
| 2022-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $8.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $6.00K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $71.00K derived: sum of 2 quarters · filed 2023-03-16 | $74.00K derived: sum of 3 quarters · filed 2023-03-16 | $93.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $68.00K derived: sum of 2 quarters · filed 2022-11-10 | $87.00K 10-Q · filed 2022-11-10 | $111.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $22.00K 10-Q · filed 2022-08-10 | $46.00K derived: sum of 3 quarters · filed 2022-08-10 | $89.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $19.00K 10-Q · filed 2022-05-11 | $43.00K derived: sum of 2 quarters · filed 2022-05-11 | $86.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $67.00K derived: sum of 2 quarters · filed 2022-03-14 | $74.00K 10-K · filed 2022-03-14 | |
| 2020-09-30 | $43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $50.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $7.00K 10-Q · filed 2021-08-10 | |||
| 2019-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $4.00K 10-K · filed 2021-03-22 | ||
| 2019-09-30 | $3.00K 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |